Table 1 Secondary outcomes and the appropriate measuring method

1. Change in the number of drugs immediately after the encounter and 6 months later

Medication list at baseline and after 6 months

2. Reason for a change, categorized in the 4 options of the algorithm, number of drugs in each category 12 months after applying the tool

Medication list of the changed medications after the intervention, with the reason for a change

3. Discrepancy in the decision to quit, change or continue the drug between PCP and patient

Medication list after intervention with any suggestion from the PCP for a change; medication list after the intervention and after shared-decision-making

4. Number of drugs for which the patient is suggesting a change

Medication lists at baseline, after 6 and 12 months

5. Number of drugs the patient is taking not known to the PCP

Medication lists at baseline, after 6 and 12 months

6. Time consumption of the intervention

Measurement of the time through the practice nurse and the PCP

7. Disease-specific variables to evaluate the course of the disease(s) for which the patient is being treated

Symptom scores and measurements of biometric analysis (e.g. blood pressure monitoring, serum glucose) and VAS scales (e.g. pain). Event rates (hospitalization, death) and unexpected adverse event rates

8. Number of drugs readopted due to an unfavorable course of the disease(s) (readoption rate)

Medication lists at baseline, after 6 and 12 months

9. Quality of life (QoL)

Patient rating on a 5-point Likert scale

EQ-5D-3 L at baseline, after 6 and 12 months

10. Barriers perceived by patients and PCPs against the approach/algorithm

Phone interview with the patients 13 months after intervention

11. Number of drugs which have been started

Medication lists at baseline, after 6 and 12 months